Continuous detection of Chikungunya Virus in a passive surveillance system in southern Thailand, 2012-2019.

Chikungunya virus (CHIKV) infections are distributed across the globe, causing significant and, often, lasting morbidity. CHIKV vaccines are in development, but their evaluation is limited by the unpredictability of CHIKV transmission, which classically manifests as explosive epidemics separated by variable interepidemic periods. A passive surveillance study for undifferentiated febrile illness was established in southern Thailand in 2012 and is ongoing.

What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients.

Purpose: Advances in therapeutic care are leading to an increase in the number of patients living with overt immunosuppression. These patients are at risk of cytomegalovirus (CMV) infection and disease that can lead to or develop during ICU admission. This manuscript aims to describe the clinical presentation, risk factors, and management of CMV infection and disease in this patient population.

The Center for Health Outcomes in Medicine Scholarship and Service (HOMES): Fostering and Supporting Physician-Initiated Research.

ProblemThe U.S. physician scholar workforce, currently comprising less than 1.

Reconciling heterogeneous dengue virus infection risk estimates from different study designs.

Uncovering rates at which susceptible individuals become infected with a pathogen, i.e., the force of infection (FOI), is essential for assessing transmission risk and reconstructing distribution of immunity in a population.

Disparities in anti-nucleocapsid and anti-spike SARS-CoV-2 antibody prevalence in NYC - April-October 2021.

Purpose: Between April-October 2021, the New York City (NYC) Health Department conducted a serosurvey to assess prevalence of SARS-CoV-2 antibodies in NYC adults as part of continued COVID-19 surveillance efforts.

Methods: Whole blood specimens were collected from 1035 adult NYC residents recruited from an annual population-based health surveillance survey. Specimens were tested for the presence of anti-SARS-CoV-2 spike protein (anti-spike) and anti-SARS-CoV-2 nucleocapsid protein (anti-nucleocapsid) antibodies.